
Prestige Estates posts 50% jump in Q2 sales; with Nomura’s ‘Buy’ call and strong outlook, see if you should invest…
Nomura predicts up to 29% rally in IndusInd Bank, with neutral views on Bank of Baroda and Kotak Mahindra—discover why…
Nomura warns Sun Pharma faces $100 million risk from potential US tariffs on specialty drugs. Explore the impact on Indian…
Nomura targets 25% upside on Titan shares citing growth potential; track festive sales and global expansion for more insights.
Accenture reported $17.6 billion revenue in Q4 FY25 with strong AI bookings. Brokerages Nuvama, JM Financial and Nomura outline what…
Discover why Nomura predicts a 25% downside for Glenmark Pharma despite its new cancer drug deal—read their analysis before investing!
Nomura maintains ‘Buy’ on Hyundai Motor India, citing GST cuts and new models; explore the potential growth opportunities now.
Discover Nomura’s top IT stock picks like Infosys and HCL Tech with up to 23% upside—see which shares to buy…
Ceat share price today, September 09: Discover why brokerages call Ceat’s $225M Camso deal a gamechanger and see the growth…
Nomura maintains Neutral on Amara Raja Energy with Rs 1,100 target. Check margin outlook, lithium-ion cell concerns, and stock performance.
S&P upgrades India’s sovereign credit rating to BBB, boosting market sentiment amid US tariff concerns. Experts say the move will…
Britannia shares drop 2% after disappointing Q1 margins despite 8% revenue growth. See what top brokerages recommend—read the latest insights.
Persistent Systems shares plunged 9% despite profit rise; review expert analyses and see if now is the time to buy…
Dixon Tech shares jump 4% after acquiring majority stake in Q Tech India; explore why Nomura sees a 29% upside!
Nomura backs Maruti Suzuki in the CAFE III debate, highlighting how India’s weight-based emissions norms unfairly penalise small, fuel-efficient cars.…
Dixon Technologies surges after bullish rating from Nomura, while Phillip Capital warns of risks; review the latest forecasts before investing!
Nomura issues ‘Buy’ calls on IndusInd Bank, Voltas, and Sun Pharma with up to 28% upside—read the full analysis to…
Nomura upgrades IndusInd Bank to ‘Buy’ with a revised target price of Rs 1,050, citing improved governance, cleaned-up books, and…